<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LEUCOVORIN CALCIUM</span><br/>(loo-koe-vor'in)<br/><span class="topboxtradename">Calcium Folinate, </span><span class="topboxtradename">Citrovorum Factor, </span><span class="topboxtradename">Folinic Acid, </span><span class="topboxtradename">Wellcovorin<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">antianemic agent</span>; <span class="classification">antidote</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 15 mg, 25 mg tablets; 3 mg/mL ampule; 50 mg, 100 mg, 350 mg vials</p>
<h1><a name="action">Actions</a></h1>
<p>A reduced form of folic acid; unlike folic acid, it does not require enzymatic reduction and therefore is readily available
         to participate in reactions.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Functions as an essential cell growth factor. When given during antineoplastic therapy, it prevents serious toxicity by protecting
         cells from the action of folic acid antagonists such as methotrexate.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Folate-deficient megaloblastic anemias due to sprue, pregnancy, and nutritional deficiency when oral therapy is not feasible.
         Also to prevent or diminish toxicity of antineoplastic folic acid antagonists, particularly methotrexate; and as adjunct with
         antifols (e.g., pyrimethamine) in pneumocystosis or toxoplasmosis to prevent significant bone marrow toxicity.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Undiagnosed anemia, pernicious anemia, or other megaloblastic anemias secondary to vitamin B<sub>12</sub> deficiency. Safe use during pregnancy (category C) or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal dysfunction.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Megaloblastic Anemia</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> No more than 1 mg/d<br/><br/><span class="indicationtitle">Leucovorin Rescue for Methotrexate Toxicity</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO/IM/IV</span> 10 mg/m<sup>2</sup> followed by 10 mg/m<sup>2</sup> q6h for 72 h, further doses based on serum methotrexate concentrations<br/><br/><span class="indicationtitle">Leucovorin Rescue for Other Folate Antagonist Toxicity</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO/IM/IV</span> 515 mg/d<br/><br/><span class="indicationtitle">Adjunct for Treatment of Pneumocystosis or Toxoplasmosis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">PO/IM/IV</span> 36 mg t.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Oral route is <small>NOT</small> recommended for doses higher than 25 mg or if patient is likely to vomit.
            			
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Use 3 mg ampules for IM injection.</li>
<li>Give deep into a large muscle.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous </span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Direct:</span> Give 1 mL (3 mg) ampules, which contain benzyl alcohol, undiluted.  <span class="methodtype">IV Infusion:</span> For doses 2, reconstitute each 50 mg in 5 mL (10 mg per 1 mL in 10 mL) of bacteriostatic water for injection with benzyl alcohol. For
                  doses &gt;10 mg/m<sup>2</sup> reconstitute, as above, but with sterile water for injection without a preservative. Final concentration is 10 mg/mL. Further
                  dilute in 100500 mL of IV solutions (e.g., D5W, NS, RL) to yield a concentration of 1020 mg/mL of IV solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give 160 mg or fraction thereof over 1 min.  <span class="methodtype">IV Infusion:</span> Do not exceed direct IV rate. Give more slowly if the volume of IV solution to be infused is large; over 1560 min, depending
                  on the volume of solution.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Droperidol,</b>
<b>fluorouracil.</b>
<span class="incompattype"> Y-site:</span>
<b>Amphotericin B cholesteryl complex,</b>
<b>droperidol,</b>
<b>foscarnet,</b>
<b>sodium bicarbonate.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Use solution reconstituted with bacteriostatic water within 7 d. Use solution reconstituted with sterile water for injection
            immediately.
         </li>
<li>Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Allergic sensitization (urticaria, pruritus, rash, wheezing). <span class="typehead">Hematologic:</span> Thrombocytosis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May enhance adverse effects of <b>fluorouracil;</b> may reverse therapeutic effects of <b>methotrexate,</b>
<b>trimethoprim-sulfamethoxazole.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> Within 30 min. <span class="typehead">Duration:</span> 36 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead"> Metabolism:</span> Metabolized in liver and intestinal mucosa to tetrahydrofolic acid derivatives. <span class="typehead">Elimination:</span> 8090% excreted in urine, 58% in feces. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor neurologic status. Use of leucovorin alone in treatment of pernicious anemia or other megaloblastic anemias associated
            with vitamin B<sub>12</sub> deficiency can result in an apparent hematological remission while allowing already present neurologic damage to progress.
         </li>
<li>Lab tests: Do Cl<sub>cr</sub> determinations prior to initiation of leucovorin, urine pH prior to and about every 6 h throughout therapy; daily serum creatinine
            levels are recommended to detect onset of kidney function impairment.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician of S&amp;S of a hypersensitivity reaction immediately (see Appendix F).</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>